Madrigal Provides Update on Timeline for Topline Results from the Phase 3 MAESTRO-NAFLD-1 Clinical Trial of Resmetirom

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/28/2026

1. ON
2. SYNA
3. SPY
4. MU
5. AAPL
6. VEON
7. SPCX
8. DRI
9. NVDA
10. FDXF

Go back to Madrigal Provides Update on Timeline for Topline Results from the Phase 3 MAESTRO-NAFLD-1 Clinical Trial of Resmetirom
(NASDAQ: MDGL) Delayed: 512.65 -1.14 (0.22%)
Previous Close $513.79    52 Week High $18.24 
Open $517.66    52 Week Low $6.60 
Day High $532.33    P/E N/A 
Day Low $505.63    EPS $0.00 
Volume 2,500,272